Cognitive effects of topiramate in migraine patients aged 12 through 17 years.

TitleCognitive effects of topiramate in migraine patients aged 12 through 17 years.
Publication TypeJournal Article
Year of Publication2010
AuthorsPandina, GJ, Ness S, Polverejan E, Yuen E, Eerdekens M, Bilder RM, Ford L
JournalPediatric neurology
Date Published2010 Mar
KeywordsAdolescent, Anorexia, Child, Cognition Disorders, Dizziness, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fructose, Humans, Male, Migraine Disorders, Neuroprotective Agents, Neuropsychological Tests, Reaction Time, Recognition (Psychology), Severity of Illness Index, Sleep Initiation and Maintenance Disorders, Space Perception, Visual Perception

Neuropsychologic data are presented from a randomized, double-blind, placebo-controlled, multicenter study with placebo, topiramate 50 mg/day, and topiramate 100 mg/day. The Cambridge Neuropsychological Test Automated Battery (CANTAB) and cognitive adverse events were used to evaluate neurocognitive effects of topiramate. Topiramate 100 mg/day vs placebo was associated with slight statistically significant score increases, indicating slowing, from baseline vs placebo in three CANTAB measures: five-choice reaction time (P = 0.028), pattern recognition memory mean correct latency (P = 0.027), and rapid visual information processing mean latency (P = 0.040). No other patterns related to topiramate treatment were observed in measurements of learning, memory, and visual information processing, except for potential improvement with topiramate 100 mg/day vs placebo in spatial span total errors (accuracy test) (P = 0.040). The most common cognitive and neuropsychiatric adverse events with a higher incidence in the topiramate 50 and 100 mg/day groups vs placebo were anorexia (9% and 11% vs 3%), insomnia (9% and 3% vs 3%), fatigue (6% and 9% vs 6%), and dizziness (6% and 9% vs 0%). Thus, topiramate 100 mg/day was associated with modest increases in psychomotor reaction times. Learning, memory, and executive function were unchanged. The tolerability profile, including cognitive adverse events, appeared to be acceptable.

Alternate JournalPediatr. Neurol.